{"id":742215,"date":"2012-05-25T06:18:00","date_gmt":"2012-05-25T06:18:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/government-of-rwanda-introduces-mercks-rotateq-rotavirus-vaccine-live-oral-pentavalent-to-help-protect-children-against-rotavirus\/"},"modified":"2023-03-22T00:04:23","modified_gmt":"2023-03-22T04:04:23","slug":"government-of-rwanda-introduces-mercks-rotateq-rotavirus-vaccine-live-oral-pentavalent-to-help-protect-children-against-rotavirus","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/government-of-rwanda-introduces-mercks-rotateq-rotavirus-vaccine-live-oral-pentavalent-to-help-protect-children-against-rotavirus\/","title":{"rendered":"Government of Rwanda Introduces Merck&#8217;s ROTATEQ\u00ae (Rotavirus Vaccine, Live, Oral, Pentavalent) to Help Protect Children Against Rotavirus"},"content":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      welcomes today\u2019s launch in Rwanda of Africa\u2019s first national rotavirus<br \/>\n      vaccination program with ROTATEQ<sup>\u00ae<\/sup> (rotavirus vaccine, live,<br \/>\n      oral, pentavalent), Merck\u2019s vaccine for the prevention of rotavirus<br \/>\n      disease. Beginning today, the first infants will receive ROTATEQ at a<br \/>\n      health center in Musanze District, Northern Province, Rwanda. Following<br \/>\n      the initial launch, ROTATEQ will be routinely administered to all<br \/>\n      infants in Rwanda as part of its national vaccination program. During<br \/>\n      2012, the Government of Rwanda Ministry of Health expects more than<br \/>\n      100,000 children will receive the vaccine.\n    <\/p>\n<p>\n      Worldwide, diarrheal infections caused by rotavirus are one of the<br \/>\n      biggest causes of childhood mortality. In Rwanda, diarrheal infections<br \/>\n      rank third among causes of death in children less than 5 years of age.<br \/>\n      Nearly 22 percent of all Rwandan children age 6 to 11 months and 25<br \/>\n      percent of children age 12 to 23 months suffer from diarrheal<br \/>\n      infections. Samples tested from October 2010 to March 2012 showed that<br \/>\n      nearly half of the infections were caused by rotavirus.\n    <\/p>\n<p>\n      \u201cWe congratulate the Government of Rwanda for the launch of this<br \/>\n      important public health initiative and applaud its efforts to help<br \/>\n      protect Rwanda\u2019s children against rotavirus-associated diarrhea through<br \/>\n      a comprehensive initiative including vaccination and other public health<br \/>\n      efforts,&#8221; said Mark Feinberg, M.D., Ph.D., chief public health and<br \/>\n      science officer, Merck Vaccines. \u201cRwanda is committed to the vaccination<br \/>\n      of their children and their accomplishments to date have been<br \/>\n      impressive. Given the impact of rotavirus gastroenteritis in children,<br \/>\n      working to help reduce severe rotavirus disease represents a critically<br \/>\n      important public health goal and we\u2019re pleased to be able to work with<br \/>\n      the GAVI Alliance to make ROTATEQ available to Rwanda and other<br \/>\n      GAVI-eligible countries worldwide.\u201d\n    <\/p>\n<p>\n      Rotavirus gastroenteritis, a leading cause of severe diarrhea in infants<br \/>\n      and young children, is highly prevalent and highly contagious, infecting<br \/>\n      nearly all children worldwide by the age of 5, often more than once. In<br \/>\n      resource-limited countries, most children experience the first episode<br \/>\n      of rotavirus diarrhea before reaching age 1. Each year, rotavirus causes<br \/>\n      approximately 111 million episodes of gastroenteritis, 25 million<br \/>\n      outpatient visits, two million hospitalizations and more than 450,000<br \/>\n      deaths in children younger than 5 years of age worldwide.\n    <\/p>\n<p>\n      ROTATEQ<sup>\u00ae<\/sup> (rotavirus vaccine, live, oral, pentavalent) is<br \/>\n      indicated for the prevention of rotavirus gastroenteritis in infants and<br \/>\n      children caused by the serotypes G1, G2, G3 and G4 when administered as<br \/>\n      a three-dose series to infants between the ages of 6 to 32 weeks. The<br \/>\n      first dose of ROTATEQ should be administered between 6 and 12 weeks of<br \/>\n      age. ROTATEQ is an oral liquid vaccine requiring no reconstitution or<br \/>\n      mixing.\n    <\/p>\n<p>\n      International organizations, such as the WHO, GAVI Alliance, the Gates<br \/>\n      Foundation and PATH, have recognized the importance of rotavirus<br \/>\n      vaccination. The Strategic Advisory Group of Experts, the principle<br \/>\n      advisory group to the WHO for vaccines and immunization, has recommended<br \/>\n      the inclusion of rotavirus vaccination in all national immunization<br \/>\n      programs since 2009 and GAVI Alliance and other stakeholders are working<br \/>\n      to make rotavirus vaccines available in the poorest countries of the<br \/>\n      world.\n    <\/p>\n<p>\n      <b>Other access efforts with ROTATEQ<\/b>\n    <\/p>\n<p>\n      With the introduction of ROTATEQ to Rwanda, Merck continues its<br \/>\n      tradition of making vaccines that address important medical needs<br \/>\n      available in resource-limited countries where the disease burden is high.\n    <\/p>\n<p>\n      In 2006, Merck introduced ROTATEQ in Nicaragua through the<br \/>\n      Merck-Nicaraguan Ministry of Health ROTATEQ Partnership. This initiative<br \/>\n      marked the first time there was access to a vaccine in the public sector<br \/>\n      of a developing country in the same year it was first licensed in a<br \/>\n      developed country. This program completed in 2009 and achieved an<br \/>\n      estimated 92 percent vaccine coverage (percent receiving third dose of<br \/>\n      ROTATEQ) among Nicaraguan infants. In March 2010, the immunization<br \/>\n      program transitioned to GAVI funding.\n    <\/p>\n<p>\n      Additionally, Merck has partnered with PATH and other organizations to<br \/>\n      better understand the safety and efficacy of ROTATEQ in Bangladesh,<br \/>\n      Ghana, Kenya, Mali and Vietnam. A clinical trial at these sites in<br \/>\n      Africa and Asia involved more than 7,500 infants and the data were<br \/>\n      published in August 2010 in the <i>Lancet<\/i>.\n    <\/p>\n<p>\n      Since 2006, ROTATEQ<sup>\u00ae<\/sup> (rotavirus vaccine, live, oral,<br \/>\n      pentavalent) has been registered and approved in more than 100 countries<br \/>\n      with more than 71 million doses distributed worldwide. ROTATEQ targets<br \/>\n      the strains of rotavirus responsible for approximately 90 percent of<br \/>\n      rotavirus disease worldwide.\n    <\/p>\n<p>\n      <b>Information about ROTATEQ<\/b>\n    <\/p>\n<p>\n      ROTATEQ is indicated for the prevention of rotavirus gastroenteritis in<br \/>\n      infants and children caused by the serotypes G1, G2, G3, and G4 when<br \/>\n      administered as a 3-dose series to infants between the ages of 6 to 32<br \/>\n      weeks. The vaccination series consists of 3 ready-to-use liquid doses of<br \/>\n      ROTATEQ administered orally starting at 6 to 12 weeks of age, with the<br \/>\n      subsequent doses administered at 4- to 10-week intervals. The third dose<br \/>\n      should not be given after 32 weeks of age.\n    <\/p>\n<p>\n      <b>Selected Safety Information about ROTATEQ<\/b>\n    <\/p>\n<p>\n      ROTATEQ should not be administered to infants with a demonstrated<br \/>\n      history of hypersensitivity to the vaccine or any component of the<br \/>\n      vaccine.\n    <\/p>\n<p>\n      Infants with Severe Combined Immunodeficiency Disease (SCID) should not<br \/>\n      receive ROTATEQ. Post-marketing reports of gastroenteritis, including<br \/>\n      severe diarrhea and prolonged shedding of vaccine virus, have been<br \/>\n      reported in infants who were administered ROTATEQ and later identified<br \/>\n      as having SCID.\n    <\/p>\n<p>\n      Infants with a history of intussusception should not receive ROTATEQ.\n    <\/p>\n<p>\n      No safety or efficacy data are available from clinical trials regarding<br \/>\n      the administration of ROTATEQ to infants who are potentially<br \/>\n      immunocompromised. No safety or efficacy data are available for<br \/>\n      administration of ROTATEQ to infants with a history of gastrointestinal<br \/>\n      disorders.\n    <\/p>\n<p>\n      Vaccine virus transmission from vaccine recipient to non-vaccinated<br \/>\n      contacts has been reported. Caution is advised when considering whether<br \/>\n      to administer ROTATEQ to individuals with immunodeficient contacts.\n    <\/p>\n<p>\n      In clinical trials, the most common adverse events included diarrhea,<br \/>\n      vomiting, irritability, otitis media, nasopharyngitis, and bronchospasm.\n    <\/p>\n<p>\n      In post-marketing experience, intussusception (including death) and<br \/>\n      Kawasaki disease have been reported in infants who have received ROTATEQ.\n    <\/p>\n<p>\n      ROTATEQ may not protect all vaccine recipients against rotavirus.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50290317&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=1&#038;md5=0b41f7e8bf2f65dd21f80e93515171fa\"><span class=\"bwuline\">vip2-msd.com\/merckcom-migrated<\/span><\/a><br \/>\n      and connect with us on Twitter, Facebook and YouTube.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes &#8220;forward-looking statements&#8221; within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. Such statements may include,<br \/>\n      but are not limited to, statements about the benefits of the merger<br \/>\n      between Merck and Schering-Plough, including future financial and<br \/>\n      operating results, the combined company\u2019s plans, objectives,<br \/>\n      expectations and intentions and other statements that are not historical<br \/>\n      facts. Such statements are based upon the current beliefs and<br \/>\n      expectations of Merck\u2019s management and are subject to significant risks<br \/>\n      and uncertainties. Actual results may differ from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      The following factors, among others, could cause actual results to<br \/>\n      differ from those set forth in the forward-looking statements: the<br \/>\n      possibility that all of the expected synergies from the merger of Merck<br \/>\n      and Schering-Plough will not be realized, or will not be realized within<br \/>\n      the expected time period; the impact of pharmaceutical industry<br \/>\n      regulation and health care legislation in the United States and<br \/>\n      internationally; Merck\u2019s ability to accurately predict future market<br \/>\n      conditions; dependence on the effectiveness of Merck\u2019s patents and other<br \/>\n      protections for innovative products; and the exposure to litigation<br \/>\n      and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2011 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50290317&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=2&#038;md5=8e432133ffdec1eb88b058d6477c4adc\"><span class=\"bwuline\">www.sec.gov<\/span><\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for RotaTeq<\/b><sup><b>\u00ae<\/b><\/sup><b><br \/>\n      at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fr%2Frotateq%2Frotateq_pi.pdf&#038;esheet=50290317&#038;lan=en-US&#038;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fr%2Frotateq%2Frotateq_pi.pdf&#038;index=3&#038;md5=ec24856bdc2ec57e7a443af420a4ddd7\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/r\/rotateq\/rotateq_pi.pdf<\/b><\/a>\n    <\/p>\n<p>\n      <b>and Patient Information for RotaTeq<\/b><sup><b>\u00ae<\/b><\/sup><b> at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fr%2Frotateq%2Frotateq_ppi.pdf&#038;esheet=50290317&#038;lan=en-US&#038;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fr%2Frotateq%2Frotateq_ppi.pdf&#038;index=4&#038;md5=8fd92dcab02743946714873c8ea44322\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/r\/rotateq\/rotateq_ppi.pdf<\/b><\/a><b>.<\/b>\n    <\/p>\n<p>\n      ROTATEQ<sup>\u00ae<\/sup> is a registered trademark of Merck Sharp &#038; Dohme<br \/>\n      Corp., a subsidiary of Merck &#038; Co., Inc., Whitehouse Station, N.J.,<br \/>\n      U.S.A.\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20120525005315r1&#038;sid=sfsite1&#038;distro=nx\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Merck<br \/>Media Contacts:<br \/>Pamela Eisele, 908-423-5042<br \/>or<br \/>Imraan        Munshi, 215-652-0059<br \/>or<br \/>Investor Contact:<br \/>Carol Ferguson,        908-423-4465     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, welcomes today\u2019s launch in Rwanda of Africa\u2019s first national rotavirus vaccination program with ROTATEQ \u00ae (rotavirus vaccine, live, oral, pentavalent), Merck\u2019s vaccine for the prevention of rotavirus disease. Beginning today, the first infants will receive ROTATEQ at a health center in Musanze District, Northern Province, Rwanda. Following the initial launch, ROTATEQ will be routinely administered to all infants in Rwanda as part of its national vaccination program. During 2012, the Government of Rwanda Ministry of Health expects more than 100,000 children will receive the vaccine. Worldwide, diarrheal infections caused by rotavirus are one of the biggest causes of childhood mortality. In Rwanda, diarrheal infections rank third among causes of death in children less than 5 years of age. Nearly 22 percent of all Rwandan children age 6 to 11 months and 25 percent of children age 12 to 23 months suffer from diarrheal<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[54,289],"class_list":["post-742215","news_item","type-news_item","status-publish","hentry","tag-corporate-responsibility-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Government of Rwanda Introduces Merck&#039;s ROTATEQ\u00ae (Rotavirus Vaccine, Live, Oral, Pentavalent) to Help Protect Children Against Rotavirus - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/government-of-rwanda-introduces-mercks-rotateq-rotavirus-vaccine-live-oral-pentavalent-to-help-protect-children-against-rotavirus\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Government of Rwanda Introduces Merck&#039;s ROTATEQ\u00ae (Rotavirus Vaccine, Live, Oral, Pentavalent) to Help Protect Children Against Rotavirus - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, welcomes today\u2019s launch in Rwanda of Africa\u2019s first national rotavirus vaccination program with ROTATEQ \u00ae (rotavirus vaccine, live, oral, pentavalent), Merck\u2019s vaccine for the prevention of rotavirus disease. Beginning today, the first infants will receive ROTATEQ at a health center in Musanze District, Northern Province, Rwanda. Following the initial launch, ROTATEQ will be routinely administered to all infants in Rwanda as part of its national vaccination program. During 2012, the Government of Rwanda Ministry of Health expects more than 100,000 children will receive the vaccine. Worldwide, diarrheal infections caused by rotavirus are one of the biggest causes of childhood mortality. In Rwanda, diarrheal infections rank third among causes of death in children less than 5 years of age. Nearly 22 percent of all Rwandan children age 6 to 11 months and 25 percent of children age 12 to 23 months suffer from diarrheal\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/government-of-rwanda-introduces-mercks-rotateq-rotavirus-vaccine-live-oral-pentavalent-to-help-protect-children-against-rotavirus\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:23+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20120525005315r1&sid=sfsite1&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/government-of-rwanda-introduces-mercks-rotateq-rotavirus-vaccine-live-oral-pentavalent-to-help-protect-children-against-rotavirus\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/government-of-rwanda-introduces-mercks-rotateq-rotavirus-vaccine-live-oral-pentavalent-to-help-protect-children-against-rotavirus\\\/\",\"name\":\"Government of Rwanda Introduces Merck's ROTATEQ\u00ae (Rotavirus Vaccine, Live, Oral, Pentavalent) to Help Protect Children Against Rotavirus - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/government-of-rwanda-introduces-mercks-rotateq-rotavirus-vaccine-live-oral-pentavalent-to-help-protect-children-against-rotavirus\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/government-of-rwanda-introduces-mercks-rotateq-rotavirus-vaccine-live-oral-pentavalent-to-help-protect-children-against-rotavirus\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20120525005315r1&sid=sfsite1&distro=nx\",\"datePublished\":\"2012-05-25T06:18:00+00:00\",\"dateModified\":\"2023-03-22T04:04:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/government-of-rwanda-introduces-mercks-rotateq-rotavirus-vaccine-live-oral-pentavalent-to-help-protect-children-against-rotavirus\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/government-of-rwanda-introduces-mercks-rotateq-rotavirus-vaccine-live-oral-pentavalent-to-help-protect-children-against-rotavirus\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/government-of-rwanda-introduces-mercks-rotateq-rotavirus-vaccine-live-oral-pentavalent-to-help-protect-children-against-rotavirus\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20120525005315r1&sid=sfsite1&distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20120525005315r1&sid=sfsite1&distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/government-of-rwanda-introduces-mercks-rotateq-rotavirus-vaccine-live-oral-pentavalent-to-help-protect-children-against-rotavirus\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Government of Rwanda Introduces Merck&#8217;s ROTATEQ\u00ae (Rotavirus Vaccine, Live, Oral, Pentavalent) to Help Protect Children Against Rotavirus\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Government of Rwanda Introduces Merck's ROTATEQ\u00ae (Rotavirus Vaccine, Live, Oral, Pentavalent) to Help Protect Children Against Rotavirus - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/government-of-rwanda-introduces-mercks-rotateq-rotavirus-vaccine-live-oral-pentavalent-to-help-protect-children-against-rotavirus\/","og_locale":"en_US","og_type":"article","og_title":"Government of Rwanda Introduces Merck's ROTATEQ\u00ae (Rotavirus Vaccine, Live, Oral, Pentavalent) to Help Protect Children Against Rotavirus - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, welcomes today\u2019s launch in Rwanda of Africa\u2019s first national rotavirus vaccination program with ROTATEQ \u00ae (rotavirus vaccine, live, oral, pentavalent), Merck\u2019s vaccine for the prevention of rotavirus disease. Beginning today, the first infants will receive ROTATEQ at a health center in Musanze District, Northern Province, Rwanda. Following the initial launch, ROTATEQ will be routinely administered to all infants in Rwanda as part of its national vaccination program. During 2012, the Government of Rwanda Ministry of Health expects more than 100,000 children will receive the vaccine. Worldwide, diarrheal infections caused by rotavirus are one of the biggest causes of childhood mortality. In Rwanda, diarrheal infections rank third among causes of death in children less than 5 years of age. Nearly 22 percent of all Rwandan children age 6 to 11 months and 25 percent of children age 12 to 23 months suffer from diarrheal","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/government-of-rwanda-introduces-mercks-rotateq-rotavirus-vaccine-live-oral-pentavalent-to-help-protect-children-against-rotavirus\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:23+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20120525005315r1&sid=sfsite1&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/government-of-rwanda-introduces-mercks-rotateq-rotavirus-vaccine-live-oral-pentavalent-to-help-protect-children-against-rotavirus\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/government-of-rwanda-introduces-mercks-rotateq-rotavirus-vaccine-live-oral-pentavalent-to-help-protect-children-against-rotavirus\/","name":"Government of Rwanda Introduces Merck's ROTATEQ\u00ae (Rotavirus Vaccine, Live, Oral, Pentavalent) to Help Protect Children Against Rotavirus - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/government-of-rwanda-introduces-mercks-rotateq-rotavirus-vaccine-live-oral-pentavalent-to-help-protect-children-against-rotavirus\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/government-of-rwanda-introduces-mercks-rotateq-rotavirus-vaccine-live-oral-pentavalent-to-help-protect-children-against-rotavirus\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20120525005315r1&sid=sfsite1&distro=nx","datePublished":"2012-05-25T06:18:00+00:00","dateModified":"2023-03-22T04:04:23+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/government-of-rwanda-introduces-mercks-rotateq-rotavirus-vaccine-live-oral-pentavalent-to-help-protect-children-against-rotavirus\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/government-of-rwanda-introduces-mercks-rotateq-rotavirus-vaccine-live-oral-pentavalent-to-help-protect-children-against-rotavirus\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/government-of-rwanda-introduces-mercks-rotateq-rotavirus-vaccine-live-oral-pentavalent-to-help-protect-children-against-rotavirus\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20120525005315r1&sid=sfsite1&distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20120525005315r1&sid=sfsite1&distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/government-of-rwanda-introduces-mercks-rotateq-rotavirus-vaccine-live-oral-pentavalent-to-help-protect-children-against-rotavirus\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Government of Rwanda Introduces Merck&#8217;s ROTATEQ\u00ae (Rotavirus Vaccine, Live, Oral, Pentavalent) to Help Protect Children Against Rotavirus"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"a1aa6e3d-656d-46ae-a67c-1dfa0ed32122","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742215","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742215\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742215"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742215"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}